Paper · 23744832

Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.

Herrera-Abreu MT and 6 others. Cancer Discov, 2013. Cited by 108 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Papers, record 23744832. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23744832

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.; PubMed
Journal: Cancer Discov; PubMed
Year: 2013; PubMed
Publication types: Journal Article, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/23744832/; PubMed
DOI: https://doi.org/10.1158/2159-8290.cd-12-0569; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC3770512/; PubMed
The journal: https://conductscience.org/library/journal-index/101561693; PubMed
Citations, by iCite: 108; iCite
Relative citation ratio, by iCite: 2.58; iCite
Revised in PubMed: 2025-05-29; PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Herrera-Abreu MT	Maria Teresa
2	Pearson A	Alex
3	Campbell J	James
4	Shnyder SD	Steve D
5	Knowles MA	Margaret A
6	Ashworth A	Alan
7	Turner NC	Nicholas C

Source PubMed

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
ErbB Receptors	Major topic
Neoplasms	Major topic
Receptor, Fibroblast Growth Factor, Type 3	Major topic
Animals
Cell Line, Tumor
Dasatinib
Gefitinib
Heterografts
High-Throughput Screening Assays
Humans
MAP Kinase Signaling System
Mice
Neoplasm Transplantation
Protein Kinase Inhibitors
Pyrimidines
Quinazolines
RNA Interference
RNA, Small Interfering
Signal Transduction
Thiazoles

Source PubMed

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	Stated by
BREAST CANCER NOW RESEARCH CENTRE	Breast Cancer Now	United Kingdom	PubMed
A11847	Cancer Research UK	United Kingdom	PubMed
C30746/A10038	Cancer Research UK	United Kingdom	PubMed
C347/A11847	Cancer Research UK	United Kingdom	PubMed
16642	Cancer Research UK	United Kingdom	PubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References43

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	21,984,977	Functional viability profiles of breast cancer.	Cancer Discov	2011	https://conductscience.org/library/papers/21984977	PubMed
2	18,552,176	Drug-sensitive FGFR2 mutations in endometrial carcinoma.	Proc Natl Acad Sci U S A	2008	https://conductscience.org/library/papers/18552176	PubMed
3	8,845,844	Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1).	Hum Mol Genet	1996	https://conductscience.org/library/papers/8845844	PubMed
4	19,381,019	Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.	J Clin Invest	2009	https://conductscience.org/library/papers/19381019	PubMed
5	11,056,689	Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE.	Breast Cancer Res	2000	https://conductscience.org/library/papers/11056689	PubMed
6	23,558,953	Identification of targetable FGFR gene fusions in diverse cancers.	Cancer Discov	2013	https://conductscience.org/library/papers/23558953	PubMed
7	19,843,843	Distinct microRNA alterations characterize high- and low-grade bladder cancer.	Cancer Res	2009	https://conductscience.org/library/papers/19843843	PubMed
8	23,298,836	The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.	J Clin Invest	2013	https://conductscience.org/library/papers/23298836	PubMed
9	20,179,196	FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.	Cancer Res	2010	https://conductscience.org/library/papers/20179196	PubMed
10	21,215,704	AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.	Cancer Cell	2011	https://conductscience.org/library/papers/21215704	PubMed

1 to 10 of 43

See all 43 references

Cited by71

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 108 citations.

PMID	Title	Journal	Year	In Papers	Source
42,177,363	FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach.	Commun Biol	2026	https://conductscience.org/library/papers/42177363	PubMed
41,870,032	Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer.	Elife	2026	https://conductscience.org/library/papers/41870032	PubMed
41,514,604	FGFR Aberrations in Solid Tumors: Mechanistic Insights and Clinical Translation of Targeted Therapies.	Cancers (Basel)	2025	https://conductscience.org/library/papers/41514604	PubMed
39,161,208	FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.	Cancer Commun (Lond)	2024	https://conductscience.org/library/papers/39161208	PubMed
39,082,679	A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants.	Cancer Res	2024	https://conductscience.org/library/papers/39082679	PubMed
39,031,286	The roles of FGFR3 and c-MYC in urothelial bladder cancer.	Discov Oncol	2024	https://conductscience.org/library/papers/39031286	PubMed
38,831,455	Targeting FGFR for cancer therapy.	J Hematol Oncol	2024	https://conductscience.org/library/papers/38831455	PubMed
38,598,298	TGFβ overcomes FGF-induced transinhibition of EGFR in lens cells to enable fibrotic secondary cataract.	Mol Biol Cell	2024	https://conductscience.org/library/papers/38598298	PubMed
38,424,198	FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.	Nat Rev Clin Oncol	2024	https://conductscience.org/library/papers/38424198	PubMed
38,378,518	Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome.	Mol Cancer	2024	https://conductscience.org/library/papers/38378518	PubMed

1 to 10 of 71

See all 71 cited by

Genes27

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
ABL1	25	PubTator's text mining	https://conductscience.org/library/genes/25	NCBI Gene
AKT1	207	PubTator's text mining	https://conductscience.org/library/genes/207	NCBI Gene
ANXA5	308	PubTator's text mining	https://conductscience.org/library/genes/308	NCBI Gene
BRAF	673	PubTator's text mining	https://conductscience.org/library/genes/673	NCBI Gene
CBL	867	PubTator's text mining	https://conductscience.org/library/genes/867	NCBI Gene
CDC25C	995	PubTator's text mining	https://conductscience.org/library/genes/995	NCBI Gene
COL11A2	1,302	PubTator's text mining	https://conductscience.org/library/genes/1302	NCBI Gene
DCTN6	10,671	PubTator's text mining	https://conductscience.org/library/genes/10671	NCBI Gene
EEA1	8,411	PubTator's text mining	https://conductscience.org/library/genes/8411	NCBI Gene
EGFR	1,956	PubTator's text mining	https://conductscience.org/library/genes/1956	NCBI Gene

1 to 10 of 27

See all 27 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23744832

GET https://conductscience.org/api/papers/v1/23744832/references?page=2

API reference For AI assistants